Nicholas Goldner, PhD

Dr. Nicholas Goldner, PhD, is a prominent figure in the biotech and healthcare industries, known for his groundbreaking work in developing novel therapies to combat treatment resistance in cancer through resistanceBio.

With a strong educational background, Dr. Goldner holds a PhD in Molecular Cell Biology from Washington University in St. Louis and a BS in Biochemistry from Wisconsin Lutheran College, where he excelled academically and laid the foundation for his future endeavors.

As the CEO and co-founder of Viosera Therapeutics, he led the development of new antibiotics targeting drug-resistant bacteria, culminating in a successful acquisition by a major pharmaceutical company in 2022.

Dr. Goldner's commitment to innovation extends beyond his entrepreneurial ventures; as a Venture Partner at Pioneer Fund, he identifies and supports early-stage founders leveraging science and technology to address complex challenges.

His tenure at resistanceBio, where he served in various key roles including CMO, Senior Vice President of Product Development, and Founder, showcases his multifaceted expertise in driving research and strategic initiatives within the organization.

A participant in the esteemed Y Combinator accelerator program, Dr. Goldner leveraged his scientific acumen and business acuity to propel Viosera Therapeutics to success, demonstrating his ability to merge cutting-edge research with commercial viability.

Driven by a passion for applying his scientific knowledge to tackle pressing healthcare issues, Dr. Goldner remains dedicated to pioneering solutions that have a meaningful impact on individuals' lives, embodying a relentless pursuit to revolutionize cancer treatment pathways and improve patient outcomes.